Clinical Trial Update: Stereotactic Radiotherapy for Oligoprogressive ER+/HER- Metastatic Breast Cancer, a Prospective Phase 2 Study (Oligopro-Breast) [NA]

View source ↗

Summary

A prospective Phase 2 study (Oligopro-Breast) is evaluating stereotactic radiotherapy for oligoprogressive, estrogen receptor-positive and HER2-negative metasta…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer
• Estrogen Receptor-positive Breast Cancer

Snippet

Sponsor: Jules Bordet Institute | Conditions: OligoProgressive Metastatic Disease | NA | Status: RECRUITING